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Abstract
Inﬂuenza A is a serious disease that causes signiﬁcant morbidity andmortality, and vaccines against
the seasonal inﬂuenza disease are of variable effectiveness. In this article, we discuss the use of the
pepitope method to predict the dominant inﬂuenza strain and the expected vaccine effectiveness in the
coming ﬂu season. We illustrate how the effectiveness of the 2014/2015 A/Texas/50/2012 [clade 3C.1]
vaccine against the A/California/02/2014 [clade 3C.3a] strain that emerged in the population can be
estimated via pepitope. In addition, we show by a multidimensional scaling analysis of data collected
through 2014, the emergence of a new A/New Mexico/11/2014-like cluster [clade 3C.2a] that is
immunologically distinct from the A/California/02/2014-like strains.
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Introduction
Inﬂuenza is a highly contagious virus, usually spread by droplet or
fomite transmission. The high mutation and reassortment rates
of this virus lead to signiﬁcant viral diversity in the population
(Ferguson et al., 2003; Rambaut et al., 2008). In most seasons
and regions, one type of inﬂuenza predominates among infected
people, typically A/H1N1, A/H3N2 or B. In the 2014/2015 season,
A/H3N2 was the most common (Flannery et al., 2015). While there
are many strains of inﬂuenza A/H3N2, typically there is a dominant
cluster of strains that infect most people during one winter season.
Global travel by infected individuals leads this cluster of sequences
to dominate in most affected countries in a single inﬂuenza season.
New clusters arise every 3–5 years by the combined effects of mutation
and selection (Smith et al., 2004; He and Deem, 2010). There is sig-
niﬁcant selection pressure upon the virus to evolve due to prior vaccin-
ation or exposure (Illingworth et al., 2014; Łuksza and Lässig, 2014).
Due to evolution of the inﬂuenza virus, the strains selected by the
World Health Organization (WHO) for inclusion in the seasonal vac-
cine are reviewed annually and often updated. The selection is based on
which strains are circulating, the geographic spread of circulating
strains and the expected effectiveness of the current vaccine strains
against newly identiﬁed strains (http://www.cdc.gov/ﬂu/professionals/
vaccination/virusqa.htm, accessed 2 July 2015). There are to date 143
national inﬂuenza centers located in 113 countries that provide and
study inﬂuenza surveillance data. Five WHO Collaborating Centers
for Reference and Research on Inﬂuenza (Centers for Disease Control
and Prevention, Atlanta, GA, USA; National Institute for Medical
Research in London, UK; Victorian Infectious Diseases Reference
Laboratory, Melbourne, Australia; National Institute of Infectious
Diseases, Tokyo, Japan; and Chinese Center for Disease Control and
Prevention, Beijing, China) are sent samples for additional analysis.
These surveillance data are used to make forecasts about which strains
are mostly likely to dominate in the human population. These forecasts
are used by the WHO to make speciﬁc recommendations about
the strains to include in the annual vaccine, in 2016 one each of a
A/H1N1, A/H3N2 and inﬂuenza B Yamagata lineage or Victoria
lineage subtype strain. Additionally, for each recommended strain there
is often a list of 5–6 ‘like’ strains thatmay be substituted bymanufacturers
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for the recommended strain and which may grow more readily in the
vaccine manufacturing process that uses hen’s eggs.
We here focus on predicting the expected effectiveness of the cur-
rent vaccine strains against newly identiﬁed strains and on predicting
or detecting the emergence of new inﬂuenza strains. Predicting effect-
iveness or emergence without recourse to animal models or human
data is challenging. The inﬂuenza vaccine protects against strains
similar to the vaccine but not against strains sufﬁciently dissimilar.
For example, the A/Texas/50/2012(H3N2) 2014/2015 Northern
hemisphere vaccine has been observed to not protect against the
A/California/02/2014(H3N2) virus. Furthermore, there is no vaccine
that provides long-lasting, universal protection, although this is an
active research topic (Kanekiyo et al., 2013).
Vaccine effectiveness is expected to be a function of ‘antigenic dis-
tance’. While antigenic distance is often estimated from ferret animal
model hemagglutination inhibition (HI) studies, the concept is more
general. In particular, in this study we are interested in the antigenic dis-
tance that the human immune system detects. A measurement
of antigenic distance that is predictive of vaccine effectiveness for
H3N2 and H1N1 inﬂuenza A in humans is pepitope (see www.
mwdeem.rice.edu/pepitope for a spreadsheet to calculate pepitope values;
Gupta et al., 2006; Pan and Deem, 2009, 2011; Pan et al., 2011). We
showhere that this approach correlateswithH3N2 vaccine effectiveness
in humans with R2 = 0.75. The quantity pepitope is the fraction of amino
acids in the dominant epitope region of hemagglutinin that differs be-
tween the vaccine and virus (Gupta et al., 2006). The structure of the
H3N2 hemagglutinin is shown in Fig. 1, and the ﬁve epitopes are high-
lighted in color. The quantity pepitope is an accurate estimate of inﬂuenza
antigenic distance in humans. Previouswork has shown that pepitope cor-
relates with inﬂuenza H3N2 vaccine effectiveness in humans with
R2 = 0.81 for the years 1971–2004 (Gupta et al., 2006). While our
focus here is H3N2, other work has shown that pepitope also correlates
with inﬂuenza H1N1 vaccine effectiveness in humans (Pan et al., 2011;
Huang et al., 2012). The pepitope measure has been extended to the high-
ly pathogenic avian inﬂuenza H5N1 viruses (Peng et al., 2014). The
pepitope measure has additionally been extended to veterinary applica-
tions, for example equine H3N8 vaccines (Daly and Elton, 2013).
To determine the strains to be included in the vaccine, the emergence
of new strains likely to dominate in the human population must be de-
tected. We here use the method of multidimensional scaling to detect
emerging strains. As an example, we apply the approach to the 2014–
15 season. Dominant, circulating strains of inﬂuenza H3N2 in the
human population typically have been present at low frequencies for
2–3 years before ﬁxing in the population. While the frequencies of
such emerging strains are low, they are high enough that samples are
collected, sequenced and deposited inGenBank.Multidimensional scal-
ing, also known as principal component analysis (Gower, 1967), has
been used to identify clusters of inﬂuenza from animal model data
(Smith et al., 2004). Thus, this method can be used to detect an incipient
dominant strain for an upcoming ﬂu season from sequence data alone,
before the strain becomes dominant (He and Deem, 2010).We here use
this method to detect emerging strains in the Northern Hemisphere
2014–15 season. Interestingly, H3N2 evolves such that the recon-
structed phylogenetic tree has a distinct one-dimensional backbone
(He and Deem, 2010; Strelkowa and Lässig, 2012).
In this article, we show that the current A/Texas/50/2012 vaccine is
predicted not to protect against the A/California/02/2014 strain that has
emerged in the population, consistent with recent observations (World
Health Organization, 2014a). This A/California/02/2014 strain can be
detected and predicted as a transition from the A/Texas/50/2012 strain.
The proposed Southern Hemisphere summer 2015 and Northern
Hemisphere 2015/2016 vaccine strain is A/Switzerland/9715293/2013,
which is identical in the expressed hemagglutinin (HA1) region to the
A/California/02/2014 strain. (There is one substitution each in epitopes
A, B and D for the A/Switzerland/9715293/2013 E4/E2 strains.)
Furthermore, we ﬁnd that there is, in 2015/2016, a transition underway
from the A/California/02/2014 cluster to an A/New Mexico/11/2014
cluster. The latter may be an appropriate vaccine component for
Northern Hemisphere 2015/2016 season, because the new A/New
Mexico/11/14 cluster is emerging and appears based upon representation
in the sequence database to be displacing the A/California/02/14 cluster.
Methods
The pepitope method
We calculate pepitope, the fraction of amino acids in the dominant epi-
tope region of hemagglutinin that differ between the vaccine and virus
(Gupta et al., 2006). We use epitope sites as in Gupta et al. (2006) and
illustrate in Fig. 1. For each of the ﬁve epitopes (see www.mwdeem.
rice.edu/pepitope for a spreadsheet to calculate pepitope values;
Gupta et al., 2006), we calculate the number of amino acid substitu-
tions between the vaccine and virus and divide this quantity by the
number of amino acids in the epitope. The value of pepitope is deﬁned
to be the largest of these ﬁve values.
Identiﬁcation of vaccine strains and circulating strains
The dominant circulating inﬂuenza H3N2 strain and the vaccine
strain were determined from annual WHO reports (World Health
Fig. 1Shown is the structure of hemagglutinin inH3N2 (accessionnumber 4O5N).
The ﬁve epitope regions (Gupta et al., 2006) are color coded: epitope A is red (19
amino acids), B is yellow (21 aa), C is orange (27 aa), D is blue (41 aa), and E is
green (22 aa). Note epitope B was dominant in 2013/2014 and 2014/2015.
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Organization, 2004, 2005, 2006a, b, 2007, 2008, 2009, 2010, 2011,
2012, 2013, 2014a, b). These strains are listed in Table I. In many
years, theWHO report lists a preferred vaccine strain, while the actual
vaccine is a ‘like’ strain. Additionally, in some years, different vaccines
were used in different regions. For each study listed in Table I, the vac-
cine strain used is listed.
Estimation of vaccine effectiveness
Vaccine effectiveness can be quantiﬁed. It is deﬁned as (Gupta et al.,
2006)
E ¼ u v
u
; ð1Þ
where u is the rate at which unvaccinated people are infected with in-
ﬂuenza and v is the rate at which vaccinated people are infected with
inﬂuenza.
The vaccine effectiveness in Equation (1) was calculated from rates
of infection observed in epidemiological studies. Inﬂuenza H3N2 vac-
cine effectiveness values for years 1971–2004 are from studies previ-
ously collected (Gupta et al., 2006). Laboratory-conﬁrmed data for
the years 2004–15 were collected from the studies cited in Table I.
Epidemiological data from healthy adults, aged ∼18–65, were used.
For each study, the total number of unvaccinated subjects (Nu), the
total number of vaccinated subjects (Nv), the number of H3N2 inﬂu-
enza cases among the unvaccinated subjects (nu) and the number of
H3N2 inﬂuenza cases among the vaccinated subjects (nv) are known
and listed in the table. From these numbers, vaccine effectiveness was
calculated from Equation (1), where u = nu/Nu and v = nv/Nv. Error
bars, ε, on the calculated effectiveness values were obtained
assuming binomial statistics for each data set (Gupta et al.,
2006): ε2 = [σ2/u2/Nv + (v/u2)2σ2/Nu], where σ2v ¼ vð1 vÞ and
σ2u ¼ uð1 uÞ.
Virus sequence data in 2013 and 2014
The evolution of the HA1 region of the H3N2 virus in the 2013/2014
and 2014/2015 seasons was analyzed in detail. We downloaded from
GenBank the 1006 human HA1 H3N2 sequences that were collected
in 2013 and the 179 humanHA1H3N2 sequences that were collected
in 2014.
Sequence data alignment
All sequences were aligned before further processing by multialign-
ment using Clustal Omega. Only full-length HA1 sequences of 327
amino acids were used, as partial sequences were excluded in the
GenBank search criterion. Default clustering parameters in Clustal
Omega were used. There were no gaps or deletions detected by
Clustal Omega in the 2013 and 2014 sequence data.
Multidimensional scaling
Multidimensional scaling ﬁnds a reduced set of dimensions that best re-
produce the distances between all pairs of a set of points. In the present
application, the points are HA1 sequences of length 327 amino acids,
and the data were reduced to n = 2 dimensions. Distances between two
sequences were deﬁned as the Hamming distance, i.e. the number of dif-
fering amino acids, divided by the total length of 327. In this way, multi-
dimensional scaling places the virus sequences in a reduced sequence
space so that distances between pairs of viral sequences are maintained
as accurately as possible. This low-dimensional clustering method en-
ables one to visualize the viruses, by ﬁnding the two best dimensions
to approximate the Hamming distances between all clustered
sequences.
Gaussian kernel density estimation
The method of Gaussian kernel density estimation was used to predict
the probability density of sequences in the reduced sequence space iden-
tiﬁed by multidimensional scaling (He and Deem, 2010). Brieﬂy, each
sequence was represented by a Gaussian distribution centered at the
position, where the sequence lies in the reduced space. The total esti-
mated viral probability density was the sum of all of these Gaussians
for each virus sequence. The weight of the Gaussian for each sequence
was constant. The standard deviation of the Gaussian for each sequence
was roughly one-half amino acid substitution in the dominant epitope,
σ = 0.5/327. In other words, the reconstructed probability density of the
viruses in the reduced (x, y) space, as estimated by the sequences from
GenBank, was given by p(x, y)∝ Σiexp{−[(x− xi)2 + (y− yi)2]/2σ2)},
where the location of virus i in the reduced space is (xi, yi) and σ is
the standard deviation. In this way, a smooth estimation of the under-
lying distribution of virus sequences from which the sequences depos-
ited in GenBank are collected is generated.
There are three criteria by which a new cluster can be judged to
determine if it will dominate in the human population in a future sea-
son. First, the cluster must be evident in a density estimation. Second,
the cluster must be growing. That is, there must be evident selection
pressure on the cluster. Third, the cluster must be sufﬁciently far
from the current vaccine strain, as judged by pepitope, for the vaccine
to provide little or no protection against the new strains. From prior
work (Gupta et al., 2006) and from the results discussed below,
peaks separated by more than roughly pepitope = 0.19 are sufﬁciently
separated that protection against the virus at one peak is expected to
provide little protection against the viruses at the other.
Results and discussion
Vaccine effectiveness correlates with antigenic distance
Figure 2 shows how vaccine effectiveness decreases with antigenic
distance. The equation for the average effectiveness (the solid line in
Fig. 2) is
E ¼ 2:417 pepitope þ 0:466:
Vaccine effectiveness declines to zero at approximately pepitope > 0.19,
on average. When the dominant epitope is A or B, in which there are
19 or 21 amino acids, respectively, this means that vaccine effective-
ness declines to zero after roughly four substitutions. When the dom-
inant epitope is C, in which there are 27 amino acids, the vaccine
effectiveness declines to zero after roughly ﬁve substitutions.
Figure 2 shows that H3N2 vaccine effectiveness in humans corre-
lates well with the pepitope measure of antigenic distance. In particular,
the Pearson correlation coefﬁcient of pepitope with H3N2 vaccine ef-
fectiveness in humans is R2 = 0.75. Interestingly, this correlation is
nearly the same as that previously reported for the 1971–2004 subset
of years (Gupta et al., 2006), despite the addition of 50% more data.
Also of signiﬁcance to note is that these correlations with pepitope are
signiﬁcantly larger than those of ferret-derived distances with vaccine
effectiveness in humans over the period 1968–2015, which are
R2 = 0.39 or 0.37 for the two most common measures (Table I and
Gupta et al., 2006).
Consistency of epitopic sites
Analysis of HA1 sites shows that of the sites under diversifying selec-
tion (Pan and Deem, 2011), there are only 10 that by this measure
should be added to the 130 known epitope sites (Gupta et al.,
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Table I. Historical vaccine strains, circulating strains and vaccine effectiveness
Year Vaccine Circulating strain Dominant
strain epitope
Pepitope Vaccine effectiveness nu Nu nv Nv d1 d2
2004–05 A/Wyoming/3/2003
(AY531033)
A/Fujian/411/2002
(AFG72823)
B 0.095 9% (Ndifon et al., 2009) 6 40 50 367 2 (Huang, 2008) 1 (Huang, 2008)
2005–06 A/New York/55/2004
(AFM71868)
A/Wisconsin/67/2005
(AFH00648)
A 0.053 36% (Skowronski et al., 2007) 43 165 6 36 1 (World Health Organization,
2006a)
2 (World Health Organization,
2006a)
2006–07 A/Wisconsin/67/2005
(ACF54576)
A/Hiroshima/52/2005
(ABX79354)
A 0.105 5% (Skowronski et al., 2009) 130 406 20 66 1 (Bulimo et al., 2008) 2 (Bulimo et al., 2008)
2007 A/Wisconsin/67/2005
(ACF54576)
A/Wisconsin/67/2005
(AFH00648)
B 0.048 54% (Fielding et al., 2011) 74 234 8 55
2008–09 A/Brisbane/10/2007
(ACI26318)
A/Brisbane/10/2007
(AIU46080)
0 51% (Simpson et al., 2015) 36 240 4 54
2010–11 A/Perth/16/2009
(AHX37629)
A/Victoria/208/2009
(AIU46085)
A 0.053 39% (World Health
Organization, 2011; Treanor
et al., 2012)
100 991 35 569 0 (European Center for Disease
Prevention and Control,
2011)
1.4 (European Center for Disease
Prevention and Control, 2011)
2011–12 A/Perth/16/2009
(AHX37629)
A/Victoria/361/2011
(AIU46088)
C 0.111 23% (World Health
Organization, 2012; Castilla
et al., 2013)
335 616 47 112 1 (Martin et al., 2015) 2.8 (Martin et al., 2015)
2012–13 A/Victoria/361/2011
(AGB08328)
A/Victoria/361/2011
(AIU46088)
B 0.095 35% (Kissling et al., 2014) 288 1257 15 100 5 (World Health Organization,
2013)
4 (World Health Organization,
2013)
2013–14 A/Victoria/361/2011
(AGL07159)
A/Texas/50/2012
(AIE52525)
B 0.190 12% (Castilla et al., 2014) 145 476 16 60 5 (World Health Organization,
2013)
4 (World Health Organization,
2013)
2014–15 A/Texas/50/2012
(AIE52525)
A/California/02/2014
(AIE09741)
B 0.191 14% (Flannery et al., 2015) 135 342 100 293 4 (World Health Organization,
2014b)
5.6 (World Health Organization,
2014b)
H3N2 inﬂuenza vaccine effectiveness in humans and corresponding pepitope antigenic distances for the 2004–15 seasons. The vaccine and circulating strains are shown for each of the years since 2004 in which H3N2 virus has
been the predominant inﬂuenza virus and for which vaccine effectiveness data are available. Vaccine effectiveness values are taken from the literature. HereNu is the total number of unvaccinated subjects,Nv is the total number of
vaccinated subjects, nu is the number of H3N2 inﬂuenza cases among the unvaccinated subjects and nv is the number of H3N2 inﬂuenza cases among the vaccinated subjects. Also shown are the distances derived from ferret HI
data by the two common measures (Gupta et al., 2006).
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2006). Alternatively, of the sites under diversifying selection, 81% are
within the known epitope regions (Pan andDeem, 2011). The 130 epi-
tope sites that we have used nearly cover the surface of the head region
of the HA1 protein, and this is why they are nearly complete. Another
recent study (Meyer and Wilke, 2015) identiﬁed epitopes somewhat
different from those that we use and further suggested that proximity
to receptor binding site is a signiﬁcant determinant of H3 evolution.
Distance from the sialic acid receptor-binding site is signiﬁcant be-
cause the sialic acid receptor-binding site is in epitope B, which is ad-
jacent to epitope A, and epitopes A and B are the most commonly
dominant epitopes over the years (Table I and Table 1 of Gupta
et al., 2006). We note, however, that upon computing the correlation
of pepitope using the four epitope sites deﬁned in Meyer and Wilke
(2015) with the human vaccine effectiveness data considered here,
one ﬁnds R2 = 0.53. This result is to be compared with the R2 = 0.75
illustrated in Fig. 2.
The inﬂuenza A/H3N2 2014/2015 season
The 2014/2015 inﬂuenza vaccine contains an A/Texas/50/2012
(H3N2)-like virus to protect against A/H3N2 viruses (World Health
Organization, 2014a). Novel viral strains detected in the human popu-
lation this year include A/Washington/18/2013, A/California/02/
2014, A/Nebraska/4/2014 and A/Switzerland/9715293/2013 (World
HealthOrganization, 2014b). It should be noted that A/California/02/
2014 and A/Switzerland/9715293/2013 are completely identical in
the HA1 sequence that contains the HA epitopes. (There is one substi-
tution each in epitopes A, B, and D for the A/Switzerland/9715293/
2013 E4/E2 strains.) Table II shows the pepitope values between the vac-
cine strain and these newly emerged strains. The values indicate, along
with Fig. 2, that the vaccine is unlikely to provide much protection
against these strains because pepitope > 0.19.
Dynamics of inﬂuenza evolution
The strains detected in 2013 and 2014 cluster in sequence space.While
the strains are sparse in the full, high-dimensional sequence space,
this clustering is detected by multidimensional scaling to the two
most informative dimensions, as shown in Fig. 3. The novel strain
A/Washington/18/2013 emerged in 2013, followed by A/California/
02/2014 and A/Nebraska/4/2014 in 2014, as shown in Fig. 3. The
latter two are sufﬁciently distinct from previous vaccine strains that
expected vaccine effectiveness is limited.
Figure 4 is an estimate of the density distribution of the inﬂuenza
H3N2HA1 sequences in years 2013 and 2014 in the low-dimensional
space provided by the multidimensional scaling. Dimensional
reduction was applied to the subset of sequences in each subﬁgure
(Fig. 4a, b or c). Then, Gaussian kernel density estimation was applied
Fig. 2 Vaccine effectiveness in humans as a function of the pepitope antigenic
distance. Vaccine effectiveness values from epidemiological studies of
healthy adults, aged approximately 18–65, are shown (triangles). Also shown
is a linear ﬁt to the data (solid, R2 = 0.75). Vaccine effectiveness declines to zero
at pepitope = 0.19 on average. The error bars show the standard estimate of the
mean of each sample point, as discussed in the text.
Table II. The pepitope distances between the vaccine strain A/Texas/50/2012(egg) and selected novel strains
Strain name Collection date pi for each epitope i Predicted effectiveness
A B C D E pepitope
A/Texas/50/2012(cell) 2012-04-15 0 0.0476 0 0.0244 0 0.0476 35%
A/Washington/18/2013 2013-11-29 0.1053 0.1905 0 0.0244 0 0.1905 0%
A/California/02/2014 2014-01-16 0.1579 0.1905 0 0.0244 0 0.1905 0%
A/Nebraska/04/2014 2014-03-11 0.1053 0.2381 0.0370 0.0244 0.0455 0.2381 0%
The pepitope distances between the vaccine strain A/Texas/50/2012(egg) and reported novel strains (World Health Organization, 2014b) in 2013 and 2014. The
pi values for each epitope (i = A–E), the number of substitutions in epitope i divided by the number of amino acids in epitope i, are also shown. The value of pepitope is the
largest of the pi values, and the corresponding epitope i is dominant. Zero values indicate no substitutions in that epitope.
Fig. 3 Dimensional reduction of all H3N2 inﬂuenza sequences collected from
humans in 2013 and 2014 and deposited in GenBank. Distances are
normalized by the length of the HA1 sequence, 327 aa. Dimensional
reduction identiﬁes the principal observed substitutions, i.e. those
correlated with ﬁtness of the virus, which we expect to be in the epitope
regions. A value of pepitope = 0.19 corresponds to a distance of 0.012 here.
Sequences from Table 2 are labeled. While the A/Texas/50/2012 sequence
was collected in 2012, substantially similar strains were collected in 2013 and
downloaded from GenBank.
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to estimate the distribution of sequences in the reduced two dimensions.
Each sequence is represented by a Gaussian function with a standard
deviation of one-half substitution in the dominant epitope.
By the criteria above, A/California/02/2014(H3N2) represented the
dominant strain circulating in the humanpopulation in 2014/2015. The
time evolution in Fig. 3, or a comparison of Fig. 4a with Fig. 4b, shows
that the A/California/02/2014 cluster emerged in 2014. Table II shows
that the distance of this new cluster from the A/Texas/50/2012(egg)
strain is pepitope > 0.19, and so from Fig. 2 the expected effectiveness
of A/Texas/50/2012(egg) against these novel A/California/02/2014-
like strains is zero. Conversely, an effective vaccine for this cluster in
the 2014/2015 ﬂu season could be A/California/02/2014, or the A/
Switzerland/9715293/2013 that is identical in the HA1 region.
Early detection of new dominant strains
Surprisingly, when we enlarge the region of sequence space considered,
going from Fig. 4b to Fig. 4c or 3, we ﬁnd another large and growing
peak at a distance pepitope = 0.24 from the A/Texas/50/2012 sequence.
This new cluster contains the A/Nebraska/4/2014 sequence. The A/
Nebraska/4/2014 sequence is pepitope = 0.16 from the A/California/02/
2014 sequence. The A/Nebraska/4/2014 sequence appears to be
dominating the A/California/02/2014 sequence in the 2015/2016 sea-
son. The consensus strain of this cluster to which A/Nebraska/4/2014
belongs is A/New Mexico/11/2014. The consensus strain minimizes
the distance from all strains in the cluster, thus maximizing expected
vaccine effectiveness. Thus, A/New Mexico/11/2014 might be a more
effective choice of vaccine for the majority of the population in com-
parison to A/Switzerland/9715293/2013 or A/California/02/2014.
Phylogenetic analysis
A systematic phylogenetic analysis of recent A/H3N2 virus HA nu-
cleotide sequences has been carried out (McAnerney et al., 2015;
Stucker et al., 2015). Brieﬂy, phylogenetic trees were reconstructed
from three reference sequence datasets using the maximum likelihood
method (Stucker et al., 2015), with bootstrap analyses of 500 repli-
cates. Dominant branches of the tree were identiﬁed with distinct
clade labels. Analysis of the HA protein sequences showed that there
were relatively few residue changes across all HA clades. The 2014
vaccine strain A/Texas/50/2012 falls into clade 3C.1, while the new
emerging A/California/02/2014 strain falls into subclade 3C.3a. The
A/Nebraska/4/2014 and the consensus A/New Mexico/11/2014
strains fall into subclade 3C.2a. The phylogenetic analysis indicates
Fig. 4 Gaussian density estimation of sequences in reduced two dimensions for (a) all 2013 H3N2 inﬂuenza sequences in humans, (b) those 2014 H3N2 inﬂuenza
sequences in humans near the A/Texas/50/2012 sequence, and (c) all 2014 H3N2 inﬂuenza sequences in humans. The consensus strain of the cluster to which A/
Nebraska/4/2014 belongs is A/New Mexico/11/2014.
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a closer relationship of A/Nebraska/4/2014 or A/New Mexico/11/
2014 to A/California/02/2014 than to A/Texas/50/2012.
Note that phylogenetic methods make a number of assumptions.
For example, substitution rates at different sites are assumed to be
the same and constant in time. Due to selection, however, substitution
rates are dramatically higher, perhaps 100×, in dominant epitope re-
gions than in non-dominant epitope or stalk regions.Multigene phylo-
genetic methods are inconsistent in the presence of reassortment, and
single-gene phylogenetic methods are inconsistent in the presence of
recombination, with the former being perhaps more signiﬁcant than
the latter in the case of inﬂuenza. Multidimensional scaling, on the
other hand, does not make either of these assumptions. MDS also nat-
urally ﬁlters out neutral substitutions that are random as the dominant
dimensions are identiﬁed. Thus, MDS provides a complementary ap-
proach to the traditional phylogenetic analysis.
Ferret HI analysis
Since an analysis showing that the correlations between the two stand-
ard methods of analyzing ferret hemagglutinin inhibition antisera as-
says with vaccine effectiveness in humans in the years 1968–2004were
R2 = 0.47 and 0.57 (Gupta et al., 2006) ﬁrst appeared, a number of
studies have reported results supporting these low correlations. For ex-
ample, Table 3 of Ansaldi et al. (2010) shows that correlation of vari-
ous immunogenicity parameters is higher with genetic distance than
with HI measures of antigenic distance. The study by Xie et al.
(2015) further illustrated the limitations of relying on ferret HI data
alone. We have updated our calculation of the correlations between
the two standardmethods of analyzing ferret hemagglutinin inhibition
antisera assays with vaccine effectiveness in humans to the years
1968–2015, see Gupta et al. (2006) and the last two columns of
Table I. The correlations with d1 and d2 are now R
2 = 0.39 and
0.37, respectively, showing that ferret HI studies have become even
less correlated with human vaccine effectiveness in recent years.
Conclusion
We have shown how vaccine effectiveness can be predicted using
pepitope values. This method requires only sequence data, unlike trad-
itional methods that require animal model data, such as ferret HI assay
experiments or post-hoc observations in humans. Interestingly, the
correlation of pepitope with H3N2 vaccine effectiveness in humans is
R2 = 0.75, nearly the same as that previously reported for the 1971–
2004 subset of years (Gupta et al., 2006), despite the addition of 50%
more data. The correlation of H3N2 vaccine effectiveness in humans
with pepitope is signiﬁcantly larger than with ferret-derived distances,
which are R2 = 0.37 or 0.37 for the two most common measures
(Gupta et al., 2006). As an application, we estimated the effectiveness
of the H3N2 vaccine strain of A/Texas/50/2012 against the observed
A/California/02/2014 strains.
Clustering of the 2013 and 2014 sequence data conﬁrms the sig-
niﬁcance of the pepitope measure. We showed from data through
2014 that there is a transition underway from the A/California/02/
2014 cluster to a A/New Mexico/11/2014 cluster. The consensus se-
quence of A/New Mexico/11/2014 from this cluster could have been
considered in late Winter 2015 for inclusion among the H3N2 candi-
date vaccine strains for the 2015/2016 ﬂu season.
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